PROSCA-BLADDR 2020 - 8th edition of the Global Congress on Prostate Cancer and the 5th edition of the Global Congress on Bladder Cancer (Virtual Meeting)
Oct 14 - Oct 15, 2020 | AntwerpBelgium
LARVOL is not affiliated with 8th edition of the Global Congress on Prostate Cancer and the 5th edition of the Global Congress on Bladder Cancer (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 5 abstracts linked to Trials
[VIRTUAL] Final overall survival (OS) analysis of PROfound: olaparib vs physician's choice of enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
[VIRTUAL] Perioperative Pembrolizumab or Placebo and Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (MIBC) Who Are Eligible for Cisplatin (KEYNOTE-866 phase 3 study)
[VIRTUAL] Perioperative Pembrolizumab or Pembrolizumab plus Enfortumab Vedotin (EV) and Cystectomy Compared to Cystectomy Alone in Patients With Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin-Ineligible (KEYNOTE-905/EV-303)
[VIRTUAL] Treatment sequencing in metastatic castration resistant prostate cancer (mCRPC) after progression under an androgen receptor signaling inhibitor (ARSI) and to docetaxel: results in long responders to previous ARSIs
[VIRTUAL] Phase 3 KEYNOTE-992 Study: Pembrolizumab Plus Chemoradiotherapy (CRT) Versus Placebo Plus CRT for Patients with Muscle-Invasive Bladder Cancer (MIBC)